An update of the etiology and management of xerostomia.
暂无分享,去创建一个
C Scully | C. Scully | S. Porter | S. Porter | S R Porter | A. Hegarty | A M Hegarty
[1] J. L. Jensen,et al. Salivary gland involvement in hypohidrotic ectodermal dysplasia. , 2008, Oral diseases.
[2] L. M. Lehman,et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. , 1995, The New England journal of medicine.
[3] K. Yoneda,et al. Treatment of xerostomia with the bile secretion-stimulating drug anethole trithione: a clinical trial. , 1999, The American journal of the medical sciences.
[4] A. Soto-Rojas,et al. The oral side of Sjögren syndrome. Diagnosis and treatment. A review. , 2002, Archives of medical research.
[5] A. Kao,et al. Impaired salivary function in patients with noninsulin-dependent diabetes mellitus with xerostomia. , 2002, Journal of diabetes and its complications.
[6] G. Lodi,et al. Oral involvement in chronic graft-vs-host disease following allogenic bone marrow transplantation. , 2002, Archives of dermatology.
[7] J. Montastruc,et al. A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs , 1997, European Journal of Clinical Pharmacology.
[8] I. Mackay,et al. Epstein-Barr virus as an etiological agent in primary Sjögren's syndrome. , 1987, Medical hypotheses.
[9] James K. Ellis,et al. Induction Paclitaxel, Carboplatin, and Infusional 5‐FU Followed by Concurrent Radiation Therapy and Weekly Paclitaxel/Carboplatin in the Treatment of Locally Advanced Head and Neck Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network , 2002, Cancer journal.
[10] Yoshiya Tanaka,et al. A PRELIMINARY STUDY ON THE INTERFERON-α TREATMENT FOR XEROSTOMIA OF SJÖGREN'S SYNDROME , 1993 .
[11] C. Avellini,et al. Chronic lymphocytic sialoadenitis in HCV‐related chronic liver disease: comparison with Sjögren's syndrome , 1997, Histopathology.
[12] J. Epstein,et al. A clinical trial of bethanechol in patients with xerostomia after radiation therapy. A pilot study. , 1994, Oral surgery, oral medicine, and oral pathology.
[13] M. A. Criswell,et al. Hyperthermic, Supersaturated Humidification in the Treatment of Xerostomia , 2001, The Laryngoscope.
[14] E. Tindall,et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. , 2002, Archives of internal medicine.
[15] B. J. Baum,et al. Salivary enhancement: current status and future therapies. , 2001, Journal of dental education.
[16] R. Fox,et al. Update in Sjögren syndrome. , 2000, Current opinion in rheumatology.
[17] A. Cooke,et al. Pilocarpine as Antagonist to the Undesired Effects of Ganglion-blocking Agents in Treatment of Hypertension , 1954, British medical journal.
[18] R. Fox,et al. Approaches to the treatment of Sjögren's syndrome. , 2000, The Journal of rheumatology. Supplement.
[19] C. Scully,et al. Adverse drug reactions in the mouth. , 2000, Clinics in dermatology.
[20] A. Nagler,et al. The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease. , 2001, Archives of oral biology.
[21] J. Büntzel,et al. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. , 2002, Seminars in radiation oncology.
[22] B. Ferguson. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer , 1994 .
[23] F. Howell,et al. Treatment of primary Sjögren's syndrome with hydroxychloroquine. , 1988, The American journal of medicine.
[24] Jensen,et al. Pretreatment symptoms and dosing regimen predict side‐effects of interferon therapy for hepatitis C , 2000, Journal of viral hepatitis.
[25] I. M. Sheppard. Oral Manifestations of Diabetes Mellitus: A Study of One Hundred Cases , 1942 .
[26] T. Daniels,et al. The cilical effects of electrostimulation on salivary function of Sjögren's syndrome patients , 1992, Rheumatology International.
[27] G. R. Davies,et al. An investigation into the use of pilocarpine as a sialagogue in patients with radiation induced xerostomia. , 2002, Australian dental journal.
[28] C. Scully,et al. HIV topic update: protease inhibitor therapy and oral health care. , 2008, Oral diseases.
[29] A. Vissink,et al. Prevention and treatment of the consequences of head and neck radiotherapy. , 2003, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[30] D. Schuller,et al. Determination of the Efficacy of Topical Oral Pilocarpine for Postirradiation Xerostomia in Patients With Head and Neck Carcinoma , 1996, The Laryngoscope.
[31] S. Yamazaki,et al. Sarcoidosis with giant parotomegaly. , 2001, Cutis.
[32] R. Riffenburgh,et al. Acupuncture for xerostomia: clinical update , 2001 .
[33] I. Mackay,et al. Primary Sjögren's syndrome after infectious mononucleosis. , 1985, Annals of internal medicine.
[34] L. Niskanen,et al. Saliva in non-insulin-dependent diabetic patients and control subjects: The role of the autonomic nervous system. , 1998, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[35] P. Fox,et al. Prednisone and piroxicam for treatment of primary Sjögren's syndrome. , 1993, Clinical and experimental rheumatology.
[36] J. Esteban,et al. Immunohistochemistry of minor salivary gland biopsy specimens from patients with Sjögren’s syndrome with and without hepatitis C virus infection , 1997, Annals of the rheumatic diseases.
[37] W. Jackson,et al. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). , 1991, Archives of internal medicine.
[38] R. Jonsson,et al. Current issues in Sjögren's syndrome. , 2002, Oral diseases.
[39] T. Suzuki,et al. Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid arthritis. , 1994, The Journal of rheumatology.
[40] H. S. Davis,et al. A Controlled Study , 1966 .
[41] M. Blom,et al. The effect of acupuncture on salivary flow rates in patients with xerostomia. , 1992, Oral surgery, oral medicine, and oral pathology.
[42] N. Rhodus,et al. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome. , 2000, The Journal of otolaryngology.
[43] O. Cameron,et al. Pilocarpine for anticholinergic adverse effects associated with desipramine treatment. , 1996, American Journal of Psychiatry.
[44] M. Rowe,et al. Sjögren's syndrome after infection by Epstein-Barr virus. , 1990, Journal of Rheumatology.
[45] Gerald. D. Levy,et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. , 1997, Arthritis and rheumatism.
[46] D. Allalouf,et al. Clinical trial of bromhexine in Sjögren's syndrome. , 1981, Annals of ophthalmology.
[47] A. Ravindran,et al. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. , 1997, The Journal of clinical psychiatry.
[48] J. Hamburger. Sjögren's syndrome as seen by an oral physician , 2001, Scandinavian journal of rheumatology. Supplement.
[49] Finn Ls,et al. What the mouth has to say about diabetes. Careful examinations can avert serious complications. , 1997 .
[50] D. Menon,et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[51] T. Lundeberg,et al. The effect of acupuncture in the treatment of patients with primary Sjögren's syndrome. A controlled study. , 1998, Acta odontologica Scandinavica.
[52] C. Scully,et al. Oral health care for the cancer patient. , 1996, European journal of cancer. Part B, Oral oncology.
[53] N. Kline,et al. Pilocarpine With Psychostimulants , 1965 .
[54] Y. Iga,et al. (+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. , 1998, Japanese journal of pharmacology.
[55] J. Epstein,et al. A clinical comparative trial of saliva substitutes in radiation-induced salivary gland hypofunction. , 1992, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.
[56] Everett Hc. The use of bethanechol chloride with tricyclic antidepressants. , 1975 .
[57] H. C. Everett. The use of bethanechol chloride with tricyclic antidepressants. , 1975, The American journal of psychiatry.
[58] Y. Takeda,et al. Sicca symptom in a patient with hemochromatosis: minor salivary gland biopsy for differential diagnosis. , 1987, International journal of oral and maxillofacial surgery.
[59] S. Bowman,et al. Collaborative research into outcome measures in Sjögren's syndrome , 2002, Scandinavian journal of rheumatology. Supplement.
[60] P. Hooper,et al. The use of salivary stimulant pastilles to improve compliance in women taking oxybutynin hydrochloride for detrusor instability: a pilot study. , 1997, British journal of urology.
[61] P. Vescovi,et al. Update on diabetes mellitus and related oral diseases. , 2004, Oral diseases.
[62] C. Scully,et al. HIV: the surgeon's perspective. Part 3. Diagnosis and management of malignant neoplasms. , 1994, The British journal of oral & maxillofacial surgery.
[63] B. Walker,et al. Hepatitis C virus infection. , 2001, The New England journal of medicine.
[64] B. Iranpour,et al. Alteration in parotid salivary flow in diabetes mellitus. , 1970, Oral surgery, oral medicine, and oral pathology.
[65] E. Bruera,et al. Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain , 1999, Supportive Care in Cancer.
[66] S. Buckley. Lacrimal and salivary secretion in Sjogren's syndrome: The effect of systemic treatment with bromhexine , 1985 .
[67] T. Daniels,et al. Effectiveness of pilocarpine in postradiation xerostomia , 1987, Cancer.
[68] P. Strang,et al. Acupuncture for Patients in Hospital-Based Home Care Suffering from Xerostomia , 1999, Journal of palliative care.
[69] M. Mravak-Stipetić,et al. Xerostomia in patients with triple A syndrome – a newly recognised finding , 2000, European Journal of Pediatrics.
[70] K. Sullivan,et al. Pilocarpine for radiation-induced xerostomia in head and neck cancer. , 2000, International journal of palliative nursing.
[71] R. Fox,et al. Sjögren's syndrome: mechanisms ofpathogenesis involve interaction of immune and neurosecretory systems , 2002, Scandinavian journal of rheumatology. Supplement.
[72] R. Fox,et al. Sjögren's syndrome , 1995, The Lancet.
[73] J. Epstein,et al. Synergistic effect of sialagogues in management of xerostomia after radiation therapy. , 1987, Oral surgery, oral medicine, and oral pathology.
[74] C. Scully,et al. Parotid salivary secretion in diabetic autonomic neuropathy. , 1991, The Journal of diabetic complications.
[75] J. Prutting. PILOCARPINE NITRATE AND PSYCHOSTIMULANTS. ANTAGONISTIC AGENT TO ANTICHOLINERGIC EFFECTS. , 1965, JAMA.
[76] P. Fox,et al. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction , 1993, Cancer.
[77] D. Schubert. Use of bethanechol chloride with phenothiazines: a case report. , 1979, American Journal of Psychiatry.
[78] A. Hill,et al. Evening primrose oil and borage oil in rheumatologic conditions. , 2000, The American journal of clinical nutrition.
[79] Yoshiyuki Suzuki,et al. Serum levels of γ-globulin and total bilirubin influence the prevalence of multiple extrahepatic complication in patients with hepatitis C virus infection , 2003 .
[80] A. van der Heide,et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. , 1993, Annals of the rheumatic diseases.
[81] S. Miyawaki,et al. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome. , 1999, Internal medicine.
[82] R. Manthorpe,et al. Effects of mouthrinses with linseed extract Salinum without/with chlorhexidine on oral conditions in patients with Sjögren's syndrome. A double-blind crossover investigation. , 2001, Gerodontology.
[83] A. B. Richards,et al. Treatment of primary Sjogren's syndrome with low-dose natural human interferon-α administered by the oral mucosal route: A phase II clinical trial , 1999 .
[84] D. Isenberg,et al. Sjögren's syndrome: a critical review of clinical management. , 2000, The Journal of rheumatology.
[85] P. Voulgari,et al. Sicca syndrome in patients with sarcoidosis , 1999, Rheumatology International.
[86] R. Yee,et al. Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sjögren's syndrome. The MGI PHARMA Sjögren's Syndrome Study Group. , 1998, Advances in experimental medicine and biology.
[87] W. Bowen,et al. Periodontal health, dental caries, and metabolic control in insulin-dependent diabetic children and adolescents. , 1987, Pediatric dentistry.
[88] K. Shiozawa,et al. A preliminary study on the interferon-alpha treatment for xerostomia of Sjögren's syndrome. , 1993, British journal of rheumatology.
[89] G. Sadler,et al. Managing the oral sequelae of cancer therapy. , 2003, Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses.
[90] M. Cohen,et al. Salivary composition in diabetic patients. , 1988, The Journal of diabetic complications.
[91] S. Arimori,et al. Clinical trial of Ambroxol in Sjogren's syndrome , 1988 .
[92] J. Horiot,et al. Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[93] P. Terasaki,et al. Association of Sjögren's syndrome with HLA-B8. , 1976, Arthritis and rheumatism.
[94] H. Moutsopoulos,et al. Antimalarials in Sjögren's syndrome--the Greek experience. , 1996, Lupus.
[95] E. Pow,et al. Salivary gland function and xerostomia in southern Chinese following radiotherapy for nasopharyngeal carcinoma , 2003, Clinical Oral Investigations.
[96] Y. Ukai,et al. Chronic anethole trithione treatment enhances the salivary secretion and increases the muscarinic acetylcholine receptors in the rat submaxillary gland. , 1984, Archives internationales de pharmacodynamie et de therapie.
[97] L. V. D. van de Putte,et al. Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatment with corticosteroids in Sjögren's syndrome , 2001, Annals of the rheumatic diseases.
[98] S. Grafakos,et al. The oral manifestations of chronic graft-versus-host disease (cGVHD) in paediatric allogeneic bone marrow transplant recipients. , 2001, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[99] R. Morton,et al. Quality of life and nutritional studies in Sjogren's syndrome patients with xerostomia. , 2001, The New Zealand dental journal.
[100] B. Angmar-Månsson,et al. Acupuncture treatment of patients with radiation-induced xerostomia. , 1996, European journal of cancer. Part B, Oral oncology.
[101] S. Singhal,et al. Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. , 1997, Leukemia & lymphoma.
[102] M. Yaron,et al. Hydroxychloroquine treatment for primary Sjögren’s syndrome: its effect on salivary and serum inflammatory markers , 1999, Annals of the rheumatic diseases.
[103] G. Sharp,et al. Prolactin levels and antinuclear antibody profiles in women tested for connective tissue disease , 1996, Lupus.
[104] S. Wei,et al. Chewing gum and saliva in oral health. , 1997, The Journal of clinical dentistry.
[105] F. Labrousse,et al. Prevalence and characteristics of Sjögren's syndrome or Sicca syndrome in chronic hepatitis C virus infection: a prospective study. , 2001, The Journal of rheumatology.
[106] A. Davies. A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer , 2000, Palliative medicine.
[107] M. Erlichman. Patient selection criteria for electrostimulation of salivary production in the treatment of xerostomia secondary to Sjogren's syndrome. , 1990, Health technology assessment reports.
[108] J. Saurat,et al. The lichen planus like and sclerotic phases of the graft versus host disease in man: an ultrastructural study of six cases. , 1981, Acta dermato-venereologica.
[109] R. Balon. Bupropion and nightmares. , 1996, The American journal of psychiatry.
[110] C. Jenkins,et al. Effects of antihypertensive medications on quality of life in elderly hypertensive women. , 1994, American journal of hypertension.
[111] C. Scully,et al. Lack of association between hepatitis C virus and Sjogren's syndrome. , 2008 .
[112] R. Müller,et al. Radiation-induced hyposalivation and its treatment with oral pilocarpine. , 1998, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[113] C. Scully,et al. Oral complications of cancer therapies: prevention and management. , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).
[114] A. Masumoto,et al. Development of Sjögren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis C , 1996, Journal of Gastroenterology.
[115] P. Fox,et al. Use of orally administered anhydrous crystalline maltose for relief of dry mouth. , 2001, Journal of alternative and complementary medicine.
[116] T. Lundeberg,et al. Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment. , 2008, Oral diseases.
[117] B. Vikram,et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[118] T. Appelboom,et al. Zidovudine in primary Sjögren's syndrome. , 1999, Rheumatology.
[119] Schubert Ds. Use of bethanechol chloride with phenothiazines: a case report. , 1979 .
[120] N. Rhodus,et al. Candida albicans levels in patients with Sjögren's syndrome before and after long-term use of pilocarpine hydrochloride: a pilot study. , 1998, Quintessence international.
[121] D. B. Ferguson. The flow rate and composition of human labial gland saliva. , 1999, Archives of oral biology.
[122] C. Ekdahl,et al. Health-related quality of life in primary Sjögren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36 , 2000, Scandinavian journal of rheumatology.
[123] R. Bartrons,et al. Fluoride and pilocarpine reduce the risk of caries produced by chronic clomipramine treatment in rats. , 1997, Caries Research.
[124] C. Scully,et al. Management of xerostomia. , 1992, Journal.
[125] J. Zacny,et al. Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers , 2000, Psychopharmacology.
[126] Salah Rs,et al. Pilocarpine for anticholinergic adverse effects associated with desipramine treatment. , 1996 .
[127] J. Groopman,et al. Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[128] A. Rubinow,et al. The use of oral pilocarpine in xerostomia and Sjögren's syndrome. , 1999, Seminars in arthritis and rheumatism.
[129] K. Sullivan,et al. Oral manifestations of chronic graft-v-host disease. , 1984, Archives of internal medicine.
[130] G. Krishnaswamy,et al. Interferon-alpha upregulates gene expression of aquaporin-5 in human parotid glands. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[131] J. Epstein,et al. Effects of compliance with fluoride gel application on caries and caries risk in patients after radiation therapy for head and neck cancer. , 1996, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[132] R. Fox,et al. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study , 1996 .
[133] K. Eguchi,et al. Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjögren’s syndrome , 1998, Annals of the rheumatic diseases.
[134] R. Weiss,et al. Human retrovirus-5 proviral DNA is rarely detected in salivary gland biopsy tissues from patients with Sjögren's syndrome. , 1997, Arthritis and rheumatism.
[135] M. Schiødt,et al. Treatment of xerostomia in patients with primary Sjögren's syndrome with sulfarlem. , 1986, Scandinavian journal of rheumatology. Supplement.
[136] N. Ogawa,et al. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome. , 2002, Arthritis and rheumatism.
[137] F. Vivino,et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. , 1999, Archives of internal medicine.
[138] J. Vincelj,et al. Pilocarpine in the prevention of postirradiation xerostomia. , 2000, Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti.
[139] S. Challacombe,et al. Patient preferences in a preliminary study comparing an intra-oral lubricating device with the usual dry mouth lubricating methods , 2002, British Dental Journal.
[140] M. Schiødt,et al. HIV-associated salivary gland disease: a review. , 1992, Oral surgery, oral medicine, and oral pathology.
[141] C. Scully,et al. Orofacial effects of antiretroviral therapies. , 2001, Oral diseases.
[142] D. Greenspan,et al. Xerostomia associated with didanosine , 1992, The Lancet.
[143] D. Horrobin. Essential fatty acid and prostaglandin metabolism in Sjögren's syndrome, systemic sclerosis and rheumatoid arthritis. , 1986, Scandinavian journal of rheumatology. Supplement.
[144] A. Nagler,et al. Parotid salivary gland dysfunction in chronic graft-versus-host disease (cGVHD): a longitudinal study in a mouse model , 2000, Bone Marrow Transplantation.
[145] P. Venables,et al. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. , 1998, The Journal of rheumatology.
[146] R. Fox,et al. Sjögren’s syndrome: current therapies remain inadequate for a common disease , 2000, Expert opinion on investigational drugs.
[147] W. S. Wilson,et al. The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. , 1995, Archives of oral biology.
[148] Rees Td. The diabetic dental patient. , 1994, Dental clinics of North America.
[149] W. H. Hall. Oral complications of cancer therapies. , 1990, Journal of neurosurgery.
[150] T. Masuhara,et al. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome. , 1994, General pharmacology.
[151] I. Katayama,et al. Oral Prednisolone Improved Acetylcholine-Induced Sweating in Sjögren's Syndrome-Related Anhidrosis , 2000, Clinical Rheumatology.
[152] R. P. Thompson,et al. Omeprazole and dry mouth. , 1995, Scandinavian journal of gastroenterology.
[153] L. Vrielinck,et al. Sicca syndrome with iron deposition in the salivary glands. , 1988, International journal of oral and maxillofacial surgery.
[154] H. Joensuu,et al. Pilocarpine and carbacholine in treatment of radiation-induced xerostomia. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[155] C. Aromdee,et al. A pilot study of the disposition of pilocarpine in plasma, saliva and urine after a single oral dose. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[156] J. Hamilton-miller,et al. A pilot study of Salix SST (saliva-stimulating lozenges) in post-irradiation xerostomia. , 1998, Current medical research and opinion.
[157] S. Arimori,et al. Clinical trial of ambroxol (Mucosolvan) in Sjögren's syndrome. , 1988, The Tokai journal of experimental and clinical medicine.
[158] S. E. Taylor,et al. Preemptive pharmacologic intervention in radiation-induced salivary dysfunction. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[159] D. Bataille,et al. Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients. , 1993, Arthritis and rheumatism.
[160] D. Samarawickrama. Saliva substitutes: how effective and safe are they? , 2002, Oral diseases.
[161] S. Singhal,et al. Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versus-host disease. , 1995, Blood.
[162] J. Bergdahl,et al. Low Unstimulated Salivary Flow and Subjective Oral Dryness: Association with Medication, Anxiety, Depression, and Stress , 2000, Journal of dental research.
[163] N. Rhodus. Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome. , 2008, Oral diseases.
[164] L. Sreebny,et al. Xerostomia in Diabetes Mellitus , 1992, Diabetes Care.
[165] E. Bruera,et al. Potential novel uses of thalidomide: focus on palliative care. , 2000, Drugs.
[166] J. M. González-Campoy,et al. What the mouth has to say about diabetes. Careful examinations can avert serious complications. , 1997, Postgraduate medicine.
[167] C. Bucca,et al. Respiratory function in systemic lupus erythematosus: relation with activity and severity , 1996, Lupus.
[168] T. Nederfors. Xerostomia: prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonists. , 1996, Swedish dental journal. Supplement.
[169] J. Schornagel,et al. Quality-of-life assessment after supradose selective intra-arterial cisplatin and concomitant radiation (RADPLAT) for inoperable stage IV head and neck squamous cell carcinoma. , 2002, Archives of otolaryngology--head & neck surgery.
[170] S. Porter,et al. The investigation of major salivary gland agenesis: a case report. , 2001, Pediatric dentistry.
[171] A. Pedersen,et al. LongoVital in the treatment of Sjögren's syndrome. , 1999, Clinical and experimental rheumatology.
[172] A. Pedersen,et al. Primary Sjögren’s syndrome: oral aspects on pathogenesis, diagnostic criteria, clinical features and approaches for therapy , 2001, Expert opinion on pharmacotherapy.
[173] F. Salaffi,et al. Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. , 1996, Clinical and experimental rheumatology.
[174] G. Wall,et al. Pharmacotherapy of Xerostomia in Primary Sjögren's Syndrome , 2002, Pharmacotherapy.
[175] A. Davies,et al. A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer , 1998, Palliative medicine.
[176] F. Vivino. The treatment of Sjögren's syndrome patients with Pilocarpine-tablets , 2001, Scandinavian journal of rheumatology. Supplement.
[177] I. Al-Hashimi,et al. A new medication for treatment of dry mouth in Sjögren's syndrome. , 2001, Texas dental journal.
[178] C. Vitali. Classification criteria for Sjögren’s syndrome , 2003, Annals of the rheumatic diseases.
[179] L. Henderson,et al. Oral health of patients with hepatitis C virus infection: a pilot study. , 2001, Oral diseases.
[180] C. Scully,et al. Hepatitis C virus infection: Review and implications for the dentist. , 1998, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[181] N. Rhodus,et al. s-IgA and cytokine levels in whole saliva of Sjögren's syndrome patients before and after oral pilocarpine hydrochloride administration: a pilot study , 1998, Clinical Oral Investigations.
[182] R. Sulkava,et al. Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. , 2001, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[183] H. Moutsopoulos,et al. Methotrexate in primary Sjögren's syndrome. , 1996, Clinical and experimental rheumatology.
[184] S. Nagataki,et al. High prevalence of Sjögren’s syndrome in patients with HTLV-I associated myelopathy , 1997, Annals of the rheumatic diseases.
[185] C. Scully,et al. Synergism between HIV and other viruses in the mouth. , 2002, The Lancet. Infectious diseases.
[186] D. Horrobin,et al. Patients with primary Sjögren's syndrome treated for two months with evening primrose oil. , 1986, Scandinavian journal of rheumatology.
[187] P. D. Dios,et al. Whole stimulated salivary flow in patients with chronic hepatitis C virus infection. , 2002, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[188] S. Rogers,et al. Health-related quality of life in patients with primary Sjögren's syndrome and xerostomia: a comparative study. , 2002, Gerodontology.
[189] A. Nagler,et al. Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study , 1999, Bone Marrow Transplantation.
[190] Stanley B. Cohen,et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. , 2002, Arthritis and rheumatism.
[191] M. Rowley,et al. Antimitochondrial autoantibodies in saliva and sera from patients with primary biliary cirrhosis , 2001, Journal of gastroenterology and hepatology.
[192] M. Ferguson. Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction. , 1993, Oral surgery, oral medicine, and oral pathology.
[193] J. Rieke,et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[194] G. Carlson,et al. The salivary glands. Embryology, anatomy, and surgical applications. , 2000, The Surgical clinics of North America.
[195] A. Nagler,et al. Histopathological study of the human submandibular gland in graft versus host disease. , 1999, Journal of clinical pathology.
[196] J. Schoenberger,et al. Self-reported side effects from antihypertensive drugs. A clinical trial. Quality of Life Research Group. , 1990, American journal of hypertension.
[197] K. Shiozawa,et al. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[198] T. Ogasawara,et al. Enhancement of salivary secretion by chronic anethole trithione treatment. , 1988, Archives internationales de pharmacodynamie et de therapie.
[199] M. Takeyama,et al. Enhancement of salivary secretion and neuropeptide (substance P, α‐calcitonin gene‐related peptide) levels in saliva by chronic anethole trithione treatment , 2001, The Journal of pharmacy and pharmacology.
[200] 明 塩沢. 口腔乾燥症状改善薬 塩酸セビメリン水和物(サリグレン®カプセル30 mg)の薬理学的特性と臨床効果 , 2002 .
[201] D. Beighton,et al. Xerostomia in patients with advanced cancer. , 2001, Journal of pain and symptom management.
[202] T. Appelboom,et al. Infliximab in primary Sjögren's syndrome: one-year followup. , 2002, Arthritis and rheumatism.
[203] R. Cowan,et al. Does salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia? , 1999, European Journal of Nuclear Medicine.
[204] J. Epstein,et al. A double-blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy. , 1999, Oral oncology.
[205] R. Riffenburgh,et al. Acupuncture for xerostomia , 2002, Cancer.
[206] T. Rees. The diabetic dental patient. , 1994, Dental clinics of North America.
[207] C. Jacobs,et al. A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. , 1996, Oncology.
[208] R. Jonsson,et al. Current concepts on diagnosis, autoantibodies and therapy in Sjögren's syndrome. , 2000, Scandinavian journal of rheumatology.
[209] P. Johnstone,et al. Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. , 2001, International journal of radiation oncology, biology, physics.
[210] Fei Liu,et al. A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer , 2000, Supportive Care in Cancer.
[211] M I Koukourakis,et al. Amifostine in clinical oncology: current use and future applications , 2002, Anti-cancer drugs.
[212] Y. Ukai,et al. Enhancement of Phosphatidylinositol Turnover and Cyclic Nucleotide Accumulation by Chronic Anethole Trithione Treatment in Rat Submaxillary Glands , 1989, The Journal of pharmacy and pharmacology.
[213] C. del Rio,et al. Diagnosis of diffuse CD8+ lymphocytosis syndrome in HIV-infected patients. , 2002, The AIDS reader.
[214] J. Connell,et al. Hydrallazine-induced Sjögren's syndrome. , 1988, International journal of oral and maxillofacial surgery.
[215] G. Lockwood,et al. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. , 2001, International journal of radiation oncology, biology, physics.
[216] F. Momm,et al. Treatment of xerostomia following radiotherapy: does age matter? , 2002, Supportive Care in Cancer.